TransCode Therapeutics Inc. SEC Form 8-K: Voting Matters Submitted to Security Holders

TransCode Therapeutics, Inc. recently submitted SEC Form 8-K regarding matters voted on by security holders. On November 22, 2024, the company held a Special Meeting of Stockholders to address several key proposals.

First up was the Ratification Proposal, which saw stockholders vote to ratify the issuance and sale of 10,000,000 shares of Common Stock through a public offering, along with warrants for ThinkEquity LLC. This proposal received 3,659,491 votes for, 1,094,753 votes against, and 70,611 votes abstained, with 4,655,205 broker non-votes.

Next on the agenda was the Reverse Stock Split Proposal, which proposed a ratio of 1-for-10 to 1-for-40 for the company’s outstanding shares of Common Stock. Stockholders approved this proposal with 7,271,421 votes for, 2,012,687 votes against, and 195,952 votes abstained, with no broker non-votes.

Lastly, the Adjournment Proposal aimed to adjourn the meeting if there were insufficient votes on the previous proposals. However, since both the Reverse Stock Split Proposal and the Ratification Proposal were approved, no adjournment was necessary. Stockholders voted with 7,738,700 votes for, 1,524,796 votes against, and 216,564 votes abstained, with no broker non-votes.

Overall, all the proposals were approved by the company’s stockholders at the Special Meeting. Detailed descriptions of these proposals can be found in the Definitive Proxy Statement filed with the Securities and Exchange Commission on October 28, 2024.